idecabtagene vicleucel
bms,2seventy bio
['bet', 'mmsm', 'karmma']
 with a wonderful presentation of the karmma cohort 2 data -&gt; orr 83% in high risk mm. meaningful results and mrd negativity in 70%! #ash22 #mmsm 
Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.